{"groups":[{"description":"All patients received melphalan (100 mg/m\\^2/day × 2; days\n\n-3 and -2), for a total dose of 200 mg/m\\^2. Patients were randomized to receive bortezomib 24 hours before administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m\\^2","id":"FG000","title":"Bortezomib Before HD Melphalan"},{"description":"patients received melphalan (100 mg/m\\^2/day × 2; days\n\n-3 and -2), for a total dose of 200 mg/m\\^2. Patients were randomized to receive bortezomib 24 hours after administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m\\^2","id":"FG001","title":"Bortezomib After HD melphalanAll"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}